A tight labor market is putting the squeeze on restaurant profits and creating a strong incentive for them to find ways to increase efficiencies.
The perfume industry has lagged behind skincare and cosmetics. To catch up, the mass market has to learn the tricks of the luxury trade.
Change is happening, but ambivalence toward the #MeToo movement remains.
Eager for foreign investment, Chinese leaders are personally committing to increased market access in a way they haven’t in years.
The law isn’t going away any time soon, and most likely isn’t going anywhere at all.
The West Coast fast-food chain needs to take advantage of buyer interest amid a flurry of restaurant dealmaking.
ABB is getting rid of its biggest business to try to make itself a little simpler. But what shareholders really need is more growth.
If it’s already getting this bad for Asos, other U.K. retailers are going to have a terrible holiday. Brexit will only make everything worse.
One year after he pleaded guilty to lying to the FBI, there is still no evidence that he is a traitor.
The breadth of investigations is so sweeping that they may hang over the president and his entourage long after Robert Mueller’s probe is finished.
China probably has become the world’s biggest economy and will reap the benefits that once flowed to the U.S.
But some independent bookstores are doing just fine.
Private equity is under pressure to spend. That’s good news for companies like Germany’s Scout24, which has only been public for three years.
The French seller of high-end personal goods needed a bigger move into experiences. Belmond is a good fit – and it can afford the high price.
The industrial giant has an analyst to thank for the surge in its shares. Many questions remain unanswered.
Would you take “Paw Patrol” away from a 4-year-old?
Buying House of Fraser has proved a costly decision for Sports Direct. But founder Mike Ashley’s strategy is still sound.
Investors rightfully want more evidence that the management team can get real results from the sensible-sounding plans it’s laid out.
The downfall of a maker of a constipation drug is a cautionary tale for fledgling pharma companies and their investors.
The $4.6 billion writedown of its digital-ad unit is the clearest signal yet that retreating from the media business is the right call.
Enrollment is down amid Trump attacks, a lack of advertising, and the end of the individual mandate.
The activist shareholder has landed on Pernod for a foray into the drinks industry. While there’s some merit to the choice, Diageo offers more value.
The South Korean auto group has more immediate concerns, such as its dismal earnings and excess cash.
Picking battles in which the odds are stacked against you isn’t smart policy, and it might not be smart politics, either.
AB InBev’s credit-rating downgrade only highlights the pain that’s to come for equity investors. Big debt-funded deals are out of the question.
Shares in Sunbelt’s British owner have had a rocky year due to fears of a U.S. slowdown. But the equipment supplier is well placed to ride out storms.
Mark Read’s first big strategic announcement after just a few months in the top role is a step in the right direction. He needs to be bolder.
Daniel O’Day has tough decisions to make about how to deploy the company’s resources.
Paula Rosput Reynolds’s arrival is a sign that Larry Culp is putting his stamp on the troubled conglomerate.
Interserve’s shareholders shouldn't expect to be left with much after the British outsourcing giant’s restructuring.
Under CEO Hiroto Saikawa, Nissan’s business performance was poor.
The U.S. stock market is too permissive about giving company founders super-voting rights in IPOs. Academic evidence shows that it’s often a liability.
The looming insolvency of the once-mighty commodities trader is a cautionary lesson to the city-state’s exchange not to drop its standards.
Here are your weekend reads.
U.S.-China tensions aren’t doing a lot of favors for Macau casinos dependent upon license renewals.
Why, exactly, was a prominent Chinese executive taken into custody?
The biotech firm is burning cash like mad, and it will be years before it has a product on the market.